REFERENCES

1. 1. Tanaka N, Nakai Y, Asakawa I, Yamaki K, Miyake M, Hori S, et al. Local dose (biologically effective dose ≥ 180 Gy2) is an important predictor of biochemical recurrence in patients undergoing low-dose-rate brachytherapy. Int J Urol. 2022; https://doi.org/10.1111/IJU.15051.
2. 1. Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, et al. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2009;73:341-6.
3. 1. Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98:275-85.
4. 1. Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H, et al. ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98:286-95.
5. 1. Stone NN, Skouteris VM, Rosenstein BS, Stock RG. I-125 or Pd-103 for brachytherapy boost in men with high-risk prostate cancer: a comparison of survival and morbidity outcomes. Brachytherapy. 2020;19:567-73.